

Subject Index

A

17-AAG, 59 (173)
A3AR agonist, 122 (384)
Abcb's, 48 (133)
ABCC1/MRP1 protein, 103 (321)
ABCG2, 176 (554)
Abiraterone acetate, 204 (655)
abl kinase, 109 (344)
ABT-737, 47 (128), 183 (581, 583)
ABT-888, 64 (189)
ACE-041, 149 (465)
Acetylation, 44 (117)
Acid sphingomyelinase (ASM), 22 (38)
Acquired drug resistance, 99 (310), 100 (312, 313), 104 (324), 105 (327)
ACTB-1003, 51 (141)
ACTB-1010, 49 (137)
Acute leukemias, 58 (168)
Acute lymphoblastic leukemia (ALL), 184 (585)
Acute myeloid leukaemia (AML), 32 (77), 113 (357), 132 (416), 159 (497)
Acute promyelocytic leukemia cells, 103 (321)
ADAM17, 47 (129)
Adenoid cystic carcinoma, 54 (154)
Advanced ovarian carcinoma (AOC), 155 (484)
AEF788, 71 (215)
AEZS-108, 120 (378)
AEZS-129, 38 (98)
AEZS-132, 66 (197)
AI1008, 109 (344)
AKT pathway, 26 (55), 28 (62), 30 (67), 33 (79), 67 (203), 83 (253)
ALB 109564(a), 181 (575)
ALDH expression, 102 (319)
ALDH inhibitors, 108 (340)
ALDH1 inhibitors, 98 (305)
ALK inhibitors, 117 (369)
Alkylating agents, 97 (300), 167 (524)
Alkyltransferase, 138 (438)
ALN-VSP, 176 (555)
alpha5beta1 integrin antagonist, 153 (476)
Alternative splicing, 112 (353)
Alveologenesis, 92 (285)
AML, 34 (84)
Amphiregulin, 154 (479)
Amuvatinib, 59 (171), 65 (193)
Anaplastic large cell lymphoma, 112 (352)
Anaplastic lymphoma kinase (ALK), 59 (170), 69 (209, 210)
Androgen receptor, 71 (218)
Angiogenesis, 23 (44), 98 (304), 149 (460, 461, 465), 155 (484)

Angiogenesis inhibitors, 66 (196)
Angiogenic pathway, 134 (422)
Animal models, 18 (27, 27A), 23 (43), 27 (57), 57 (163), 58 (167), 67 (200), 110 (346), 151 (471), 186 (594), 203 (652)
Anthracyclines, 105 (330), 120 (378), 130 (411), 143 (452), 180 (572), 182 (577)
Anti-angiogenics, 179 (567), 188 (599), 204 (653)
Anti-angiopoietin antibodies, 150 (468), 156 (489)
Anti-CXCR54 antibody, 74 (225), 78 (241)
Anti-death receptor 5 antibodies, 132 (415)
Anti-DLL4 antibody, 73 (222), 74 (227)
Anti-HER3 antibodies, 73 (224), 76 (234)
Anti-IGF antibodies, 3 (3LB)
Anti-IGF1R therapy, 75 (229)
Anti-mitotic agents, 160 (501)
Anti-NRP1 antibodies, 118 (372)
Anti-receptor antibodies, 82 (251), 83 (2LB)
Anti-RON antibodies, 3 (2LB)
Anti-VEGFR antibodies, 75 (231), 150 (468), 155 (483)
Antibody–drug conjugates, 35 (86), 73 (223), 76 (235), 77 (236, 237), 152 (472)
Antibody–maytansinoid conjugates (AMCs), 76 (235), 77 (236)
Anticalins, 76 (233)
Antimetabolites, 67 (203)
Antisense-based therapy, 26 (53), 51 (144), 71 (218), 81 (247), 98 (307), 113 (359), 168 (527), 169 (530)
Antp-TPR peptide, 32 (76)
Apaf-1 mislocalization, 198 (631)
APO866, 4 (5LB)
Apoptosis, 26 (56), 87 (267), 92 (286), 96 (297), 99 (309), 106 (331), 109 (343), 139 (440), 182 (578), 183 (582, 583), 184 (585, 586), 185 (588, 589), 186 (591), 204 (653)
Apoptosis-inducing compounds, 63 (188)
AraC, 159 (497)
ARQ 087, 44 (119)
ARQ 197, 142 (451)
AS703569, 133 (418)
AS703569/R763, 157 (493)
Assay validation, 3 (1LB), 21 (36)
***Astragalus* total saponins**, 138 (437)
AT13387, 187 (596)
AT9283, 163 (512)
ATF3, 105 (327)
AT7519M, 157 (491)
ATP-based assays, 95 (295)
Atrimers, 106 (331)
Aurora kinases, 32 (75), 49 (137), 133 (418), 157 (493), 158 (496), 159 (497), 160 (502)

Autophagy, 183 (582), 184 (586), 186 (593)

Axl expression, 200 (639)

Axon guidance molecule Slit2, 156 (487)

Azacitidine, 163 (510)

Azacytidine, 174 (550)

AZD1152, 159 (497)

AZD8055, 55 (157)

AZD8931, 151 (471)

B

B-cell lymphomas, 198 (631)

B lineage acute lymphoblastic leukemia, *TEL/AML1* subset, 199 (636)

B-Raf inhibitor, 31 (71)

BAFF receptor aptamers, 81 (247)

BAY853474, 53 (152)

BAY 1000394, 158 (495)

BAY 869596, 186 (594)

BAY 80-6946, 50 (138), 140 (444)

BAY 86-9766, 50 (138, 140), 53 (151), 116 (368)

Bcl-2, 153 (478)

Bcl-2 expression, 192 (611)

Belinostat, 62 (184)

Bendamustine, 90 (277)

Berberine, 186 (591)

Berubicin, 180 (572), 182 (577)

β -Catenin, 26 (53), 31 (72), 174 (548)

Bevacizumab, 30 (70), 131 (413), 134 (421), 137 (432), 150 (467)

BEZ235, 35 (87)

B16F10 melanoma model, 67 (200)

BH3 mimetics, 57 (166), 69 (211)

BI 811283, 158 (496), 160 (502)

BIBW2992, 44 (118), 51 (143), 68 (204)

Bicalutamide, 62 (184), 163 (510)

BIIB024, 40 (105)

BIO, 114 (360)

Bioluminescence imaging (BLI), 85 (261), 86 (263), 87 (269), 89 (273, 274), 91 (280, 282)

Biomarkers, 3 (1LB, 2LB), 13 (10, 7), 16 (18), 18 (27), 19 (28), 105 (327), 177 (559), 179 (568), 187 (595), 188 (599), 190 (605, 606), 191 (607, 608, 609), 192 (611, 612), 193 (614), 194 (618, 619), 196 (624, 625, 627), 200 (638, 639), 201 (642, 643), 202 (647, 648), 203 (651)

Biomarkers for adenoma–carcinoma transition, 202 (646)

Biosample collection, 13 (10)

Birt–Hogg–Dubé syndrome, 37 (95)

Bladder cancer, 192 (612), 196 (625)

Blood–brain barrier, 48 (133), 59 (170), 136 (429), 176 (554)

Bmi-1, 98 (306)

BMS-754807, 131 (412)

BMS-794833, 41 (106)

BMS-817378, 38 (96)

Bone metastases, 62 (181), 85 (260), 190 (604)

Bortezomib, 36 (91), 100 (314), 162 (509), 183 (580)

Bosutinib, 127 (401), 133 (419)

BRAF inhibitors, 139 (441)

Branched peptides, 33 (80)

BRCA deficiency, 4 (6LB)

BRCA, 61 (179), 64 (189), 81 (244), 114 (362), 128 (405), 132 (417), 197 (630)

Breast cancer, 30 (70), 32 (75), 34 (83), 35 (86), 36 (90), 37 (94), 46 (126), 47 (129), 49 (136), 58 (169), 60 (175), 64 (189), 89 (276), 93 (287), 94 (292), 101 (315), 104 (324), 107 (336), 108 (340), 128 (405), 136 (428), 139 (440), 156 (486), 157 (493), 158 (495), 173 (544),

175 (552, 553), 178 (563, 564), 187 (595), 190 (604), 197 (630), 198 (632), 204 (655)

BT-062, 74 (226)

Burkitt's lymphoma, 171 (537)

C

C-1305, 113 (357)

C-1311, 185 (587)

c-FLIP, 184 (584), 185 (589), 186 (591)

c-kit expression, 200 (641)

c-Met activation, 155 (485)

c-Met antagonists, 162 (508)

c-MET:HGF paracrine axis, 88 (272)

c-myc expression, 171 (537)

Calcium channel agonists, 119 (376)

Calixarene derivatives, 154 (480)

Camptothecin, 134 (423)

Camptothecin conjugates, 180 (570)

Camptothecins, 55 (156)

Cancer progression, 99 (310)

Cancer stem cells, 73 (222), 107 (335), 149 (462), 197 (628), 200 (640, 641)

Cancer stem-like cells, 98 (306), 102 (319), 108 (340), 151 (470)

Cancer target screening, 177 (560)

Canine tumour cells, 91 (281)

Capecitabine, 36 (90), 141 (448)

Carbohydrate/fat-restricted diet, 67 (200)

Carboplatin, 39 (100), 130 (410), 131 (412), 134 (421), 150 (467)

Caspase 8, 185 (589)

Caspase-3 fluorescent probe, 87 (267)

Castration-resistant prostate cancer (CRPC), 42 (111), 57 (163), 58 (167), 71 (218), 129 (406), 136 (430)

Cathepsins, 22 (38), 184 (586)

Caveolin-1 silencing, 159 (499)

CB3, 47 (127)

CCK-2R, 47 (130)

CCR5 polymorphisms, 182 (579)

CD133, 45 (121)

CD138, 74 (226)

CD133 antibodies, 194 (620)

CD20 antibodies, 75 (232)

CD9 expression, 199 (636)

Cdc7 inhibitors, 122 (385)

Cdc7 kinase, 161 (505)

Cdk9, 161 (505)

CDK inhibitors, 140 (445), 158 (495)

Cell cycle arrest, 161 (504)

Cell differentiation-inducing agents, 95 (296)

Cell division inhibitors, 95 (294)

Cell growth inhibition, 107 (334)

Cell membrane conductance, 139 (439)

Cell motility regulation, 156 (487)

Cell panel for drug evaluation, 145 (459)

Cell-penetrating peptides, 135 (424)

Cell signaling, 190 (605)

CellSearch CTC profile kit, 196 (626)

Cellular drug response, 105 (329)

Cellular programming, 185 (590)

CEP-18770, 93 (288), 120 (379)

Cervical cancer, 111 (351), 114 (360)

Cetuximab, 39 (101), 59 (172), 62 (182), 63 (186), 113 (358)

CF102, 122 (384)

CH5132799, 32 (74), 41 (108), 45 (122)

CH5164840, 34 (81), 37 (92)

- Chemokines**, 74 (225), 78 (241)
Chemoprevention, 203 (652)
Chemosensitization, 33 (78), 157 (492)
Chemotherapy, 87 (267)
Chemotherapy-induced vascular toxicity, 143 (452)
Chk1, 65 (194), 67 (201)
CHK inhibitors, 157 (492), 158 (494)
Chk1 pathway, 81 (243)
Cholangiocarcinoma, 52 (146)
Cholesterol-based lipids, 169 (529)
Chondrosarcoma, 42 (112)
CHR-3996, 125 (394)
Chronic lymphocytic leukemia (CLL), 57 (166), 161 (505)
Chronic myelogenous leukemia, 127 (401)
CIP2A downregulation, 162 (509)
Circulating tumour cells, 156 (486), 191 (610), 195 (621), 196 (626), 198 (632)
Circulating tumour cells, prognostic value, 189 (603)
Cisplatin, 35 (85), 52 (145), 105 (327), 166 (521), 182 (578)
CL-ONC1, 23 (45)
Clathrin-mediated pathway, 169 (529)
CLT-28643, 153 (476)
CNX-1351, 37 (93)
Colon cancer, 29 (66), 45 (120), 75 (229), 92 (283), 112 (354), 138 (437)
Colon carcinoma, 196 (624)
Colon tumourgraft models, 88 (270)
Colonoscopy, 86 (264)
Colorectal cancer, 39 (102), 50 (140), 51 (143), 56 (161), 59 (172), 61 (180), 62 (182), 71 (215), 97 (301), 107 (335), 108 (339), 111 (350), 149 (462), 152 (473), 183 (583), 185 (589), 202 (646), 205 (658)
Colorectal liver metastases, 152 (474)
Combination high-throughput screening (cHTS), 96 (298)
Combination therapy, 4 (4LB), 15 (17), 16 (21, 22), 17 (23), 22 (41), 25 (50), 26 (54, 56), 27 (57, 58), 28 (60), 29 (66), 30 (70), 32 (75, 77), 34 (81, 84), 35 (85, 86), 36 (89, 90), 39 (100, 99), 40 (103), 45 (122), 48 (132), 50 (140), 59 (172), 64 (189), 65 (193), 66 (196), 67 (201, 203), 68 (207), 70 (213), 94 (291, 292), 97 (302), 98 (304, 305), 99 (309), 103 (323), 111 (350), 117 (370), 122 (386), 124 (390), 125 (395), 126 (396), 130 (410, 411), 131 (412, 413), 133 (418), 134 (421), 136 (430), 137 (432, 433), 138 (437), 149 (460, 463), 155 (483), 158 (494, 495), 159 (497), 164 (515), 165 (516, 517), 166 (522), 170 (535), 178 (565), 184 (585)
Companion diagnostics, 201 (645)
Cooperative/synergistic effects, 4 (6LB), 47 (128), 53 (150), 57 (166), 59 (171, 173), 62 (184), 63 (186, 188), 67 (203), 71 (218), 78 (239), 94 (291, 292), 96 (298), 97 (302), 102 (320), 103 (323), 104 (326), 105 (328), 137 (433), 138 (437), 165 (517, 518), 176 (556), 183 (582, 583), 186 (591)
CP-4126, 135 (426)
Creatine kinase, 142 (449)
CREB, 52 (148)
Crizotinib, 117 (369)
CRLX288, 135 (425)
Cross-regulatory loops, 113 (359)
Crosstalk between signal pathways, 194 (618)
CS-1008, 78 (240)
CS-7017, 101 (316)
CS-7017 bioavailability, 104 (325, 326)
CSC model, 9 (3), 10 (4, 5)
CSF-1R, 50 (139)
CU-201, 63 (185)
CUDC-101, 115 (364)
CX-4945, 39 (99), 131 (414), 165 (518)
CXR1002, 45 (123), 124 (391)
CYP3A5, 175 (553)
CYP3A5*3, 175 (552)
CYP3A4 inhibitors, 104 (326)
CYP2D6, 175 (553)
Cytarabine, 32 (77)
Cytochrome P450 inhibitors, 181 (573)
Cytoplasmic mislocalization, 156 (488)
- D**
D-3263 HCl, 119 (376)
Dalotuzumab, 75 (229)
Darinaparsin, 161 (506)
Dasatinib, 59 (172), 63 (186), 83 (254)
DCE-MRI, 151 (469)
Deacetylase inhibitors, 124 (392)
Deacetylation, 25 (51)
Death receptor 5 (DR5), 78 (240)
Dermal fibroblasts, 144 (456)
Dextromethorphan phenotyping, 204 (654)
Diarrhea, 143 (454)
Diffuse large B-cell lymphoma (DLBCL), 180 (572)
Dipyridamole, 34 (84)
Disulfide linker, 76 (235)
DM-CHOC-PEN, 144 (458)
DNA amplification, 20 (34)
DNA binding, 137 (434)
DNA-binding agents, 105 (329)
DNA damage/repair, 55 (156), 65 (193), 81 (244, 245), 163 (511), 164 (513, 514), 165 (518), 166 (519, 520, 521), 167 (523, 524), 182 (578)
DNA-dependent protein kinase, 161 (507), 164 (514)
DNA methylation, 13 (9), 173 (544, 546, 547), 174 (549, 550), 191 (609)
DNA triplex formation, 170 (532)
DNA vaccines, 24 (49), 25 (4LB, 5LB, 6LB)
DNAzymes, 60 (175)
Docetaxel, 32 (75), 36 (90), 124 (390), 126 (396), 130 (410), 135 (425), 136 (430), 175 (552)
Docetaxel, radiolabeled, 182 (576)
Dolichol metabolism, 144 (456)
Doxorubicin, 105 (330), 124 (390)
DPAGT1, 105 (330)
Drug assessment, 3 (3LB), 90 (277, 279), 91 (280, 281), 92 (283, 284), 93 (289), 94 (291), 96 (299), 97 (300), 101 (316), 113 (358), 114 (362), 117 (371), 119 (376), 120 (378, 379, 380), 121 (381, 383), 123 (387, 388, 389), 124 (390, 391, 392), 125 (393, 394), 126 (397, 398), 127 (400, 401), 128 (403, 404), 129 (406, 407, 408), 130 (409), 131 (412, 414), 132 (415), 133 (419), 134 (421, 423), 135 (426), 136 (430), 137 (432, 434), 142 (451), 152 (472), 153 (476), 157 (491), 158 (496), 159 (498), 160 (501, 502), 161 (506), 163 (512), 164 (515), 165 (516), 166 (522), 171 (536, 537), 172 (540, 542), 180 (570, 571, 572), 203 (651), 204 (655)
Drug characterization, 4 (5LB), 52 (147), 53 (149, 152), 61 (178), 65 (194), 71 (216), 93 (288), 95 (294, 296), 96 (298), 108 (338), 109 (342, 344), 110 (345), 117 (369), 118 (373, 374), 128 (405), 132 (417), 133 (420), 137 (431), 154 (482), 158 (495), 160 (503), 168 (528), 169 (531), 181 (573, 574), 182 (576), 183 (581), 185 (587), 186 (591, 592), 189 (601), 190 (605), 199 (637), 204 (653), 206 (661)
Drug combination screening, 48 (131)
Drug delivery, 135 (424, 425), 136 (428), 169 (529), 189 (601)

- Drug delivery modelling**, 135 (427)
- Drug design**, 30 (69), 31 (72, 73), 32 (76), 37 (92, 93), 61 (177), 62 (183), 76 (233), 96 (297), 136 (429), 140 (445), 141 (447), 154 (480), 168 (528), 171 (539), 176 (557), 178 (562)
- Drug development**, 9 (1), 13 (7), 14 (13), 15 (16, 17), 16 (19, 20, 21), 18 (27), 19 (28), 20 (30, 31, 32), 44 (119), 92 (284), 94 (290, 293), 138 (438), 167 (525), 187 (595)
- Drug discovery**, 38 (96), 39 (102), 41 (108), 43 (113, 115), 45 (120), 47 (127), 72 (219, 220), 87 (268), 112 (353), 139 (441, 442), 140 (443, 444), 141 (446), 160 (501), 168 (526), 170 (532), 173 (547)
- Drug dosing**, 13 (11), 92 (286), 115 (363, 364, 365), 116 (366, 368), 118 (372, 374), 119 (375, 376, 377), 121 (381), 122 (384, 385), 123 (389), 124 (391, 392), 125 (393, 394, 395), 126 (396), 127 (400), 128 (403, 404), 130 (409), 131 (412, 414), 132 (415), 133 (419), 134 (421, 423), 135 (426), 136 (430), 137 (434), 143 (453, 454), 149 (465), 152 (472), 157 (491), 158 (496), 163 (512), 165 (516), 172 (540), 174 (550), 180 (570)
- Drug mechanism**, 206 (659)
- Drug resistance**, 9 (2), 10 (5), 39 (101), 83 (252, 253), 102 (318, 319), 103 (322), 109 (341)
- Drug resistance markers**, 198 (631)
- Drug screening**, 95 (294, 295), 96 (299), 113 (356), 178 (562)
- Drug synthesis**, 37 (92), 60 (176), 67 (202), 96 (297)
- Drug tailoring**, 13 (7)
- Drug toxicity**, 142 (449, 450, 451), 143 (452, 453, 454), 144 (455, 456, 457, 458), 145 (459), 175 (552), 176 (557)
- Drug transporters**, 14 (12)
- Drug–biomarker co-development**, 179 (568)
- Drug–drug interactions**, 13 (11), 101 (316), 121 (382), 149 (460)
- Dual-mechanism inhibitors (DMI)**, 27 (58)
- Ductal breast carcinoma**, 197 (629)
- DX-2802**, 157 (490)
- E**
- E7080**, 143 (453), 144 (455)
- E7820**, 133 (420)
- E-3810**, 64 (191)
- E-cadherins**, 151 (470)
- ECG analysis**, 172 (542), 206 (661)
- ECMC Initiative**, 16 (19)
- Eg5 inhibitors**, 3 (1LB)
- EGFR**, 39 (101)
- EGFR amplification**, 202 (649)
- EGFR antibodies**, 62 (182), 63 (187)
- EGFR inhibitors**, 47 (129), 68 (204, 206), 115 (364), 192 (613)
- EGFR internalization**, 99 (308)
- EGFR polymorphisms**, 175 (551)
- EGFR translocation**, 166 (521)
- ELISA measurement of activated EGFR**, 192 (613)
- Embryonic stem cells**, 202 (647)
- EMD 1214063**, 71 (216)
- EML4-ALK signaling**, 54 (155)
- Endocytosis**, 169 (529)
- Endoglin**, 116 (367)
- Endometrial cancer**, 120 (378)
- Endometrial carcinomas**, 55 (159)
- Endoplasmic reticulum (ER) stress**, 45 (123), 53 (150), 138 (435), 183 (580)
- Endothelins**, 42 (111), 56 (161), 101 (317), 174 (548)
- Endoxifen exposure**, 204 (654)
- Endpoints**, 19 (29), 23 (45)
- Ependymomas**, 70 (214)
- EphA2–ephrinA1 binding**, 94 (293)
- Epigenetic drugs**, 13 (9)
- Epigenetic silencing**, 127 (399)
- Epirubicin**, 130 (411)
- Epithelial ovarian cancer**, 101 (317)
- Epithelial phenotype**, 94 (292)
- Epithelial–mesenchymal transition (EMT)**, 21 (37), 71 (217), 94 (292), 101 (317), 114 (361), 119 (377), 137 (431), 152 (473, 474), 155 (485), 170 (535), 191 (609)
- erbB**, 151 (471)
- ERBB3**, 172 (541)
- ErbB activation**, 107 (337)
- ErbB2 inhibitors**, 55 (157)
- Eribulin**, 181 (573)
- Eribulin mesylate**, 181 (574)
- ERK pathway**, 196 (627)
- Erlotinib**, 30 (68), 50 (138), 62 (181), 68 (207), 98 (304), 125 (395), 183 (582), 191 (609), 193 (614)
- Esomeprazole**, 101 (316)
- Esophageal squamous cell carcinoma**, 170 (534)
- ETA receptor antagonists**, 56 (161)
- Etoposide**, 59 (171)
- ETP-46321**, 49 (134)
- Everolimus**, 42 (112), 65 (195)
- Ex vivo assay for drug response monitoring**, 202 (648)
- External quality assurance for molecular diagnostics**, 201 (645)
- EZN-4176**, 71 (218)
- F**
- F14512**, 89 (273)
- F8-IL2 antibody**, 78 (239)
- Farnesyltransferase inhibitors**, 64 (192)
- Farnesoid X receptor expression**, 190 (604)
- Fatty acid synthase (FASN) inhibitors**, 110 (347)
- FDG PET/CT**, 195 (623)
- FGF trap FP-1039**, 121 (381)
- FGFR**, 44 (119), 51 (141), 64 (191), 75 (230)
- FGFR inhibitors**, 72 (220)
- FGFR4 polymorphism**, 108 (339)
- Fibrosarcoma**, 153 (477)
- Fisetin**, 139 (440)
- FISH**, 195 (621), 196 (626), 202 (649)
- FISH-S protocol**, 192 (612)
- FLT3 downregulation**, 185 (587)
- Fluorescence correlation spectroscopy (FCS)**, 113 (356)
- Fluorescence cross-correlation spectroscopy (FCCS)**, 113 (356)
- Focal adhesion kinase**, 42 (110)
- Folate receptor 1**, 77 (236)
- FOLFOX6**, 117 (370)
- Foretinib**, 42 (109)
- Fosbretabulin tromethamine**, 150 (467)
- Fra-1**, 170 (534)
- Fragment based drug discovery (FBDD)**, 186 (592)
- 5-FU**, 36 (90), 102 (320)
- FUS-CHOP gene**, 102 (318)
- G**
- G-quadruplex binding small molecule**, 111 (348)
- G-quadruplex ligands**, 55 (156)
- GA101**, 75 (232)
- Gadobutrol**, 151 (469)
- Ganoderma lucidum**, 137 (431)
- Gastric cancer**, 42 (109), 97 (303), 102 (320), 138 (435), 156 (488)

Gastrin, 47 (130)
Gastrointestinal cancer, 117 (370)
Gastrointestinal stromal tumors (GIST), 69 (211)
Gastrointestinal tract tumours, 89 (274)
GDC-0068, 33 (79), 190 (605)
GDC-0152, 34 (82), 125 (393)
GDC-0941, 47 (128), 48 (132, 133), 51 (142), 134 (421), 187 (595)
GDC-0973, 48 (132)
GDC-0980, 123 (389)
GDEPT therapy, 167 (525)
Gefitinib, 98 (307), 99 (308)
Gemcitabine, 25 (50), 35 (85), 52 (145), 69 (208), 94 (292), 124 (390), 133 (418), 158 (494), 165 (518), 176 (556)
Gemcitabine analog, 135 (426)
Gene expression, 21 (36, 37)
Gene expression profiling, 14 (13), 30 (68)
Gene profiling, 90 (278), 98 (304), 155 (484), 190 (606), 195 (622), 197 (630)
Gene signatures, 178 (563), 191 (609)
Genetic cancer risk factors, 182 (579)
Genotyping, 21 (35)
GIST, 83 (252)
Glioblastoma, 27 (57), 30 (67), 48 (133), 98 (305), 111 (349), 194 (620)
Glioblastoma model, 87 (268)
Glioblastoma multiforme, 45 (121), 52 (148), 60 (176)
Glioma, 36 (89), 113 (359)
Glucocorticoid-induced tumour survival, 142 (450)
Glucosylceramide synthase inhibitors, 105 (328)
GMX1778, 4 (5LB)
GNE-900, 157 (492)
Grb2 adaptor protein, 112 (352)
GSK1120212, 118 (373)
GSK3 inhibitors, 114 (360, 361)

H

515H7, 74 (225), 78 (241)
Hbo1 expression, 179 (566)
Head and neck cancer, 63 (186), 66 (198), 102 (319), 179 (567), 201 (644)
Heat shock proteins, 22 (38), 27 (59), 28 (61), 32 (76), 34 (81), 37 (92), 52 (147), 59 (173), 69 (210), 99 (310), 119 (375), 153 (478), 187 (596), 189 (602)
Hedgehog inhibitors, 67 (202)
Hedgehog signaling, 60 (174), 67 (202), 152 (475)
Hematopoietic malignancies, 72 (219)
Hepatoblastoma, 177 (561)
Hepatocarcinogenesis, 203 (652)
Hepatocellular carcinoma (HCC), 53 (151), 64 (190, 192), 70 (212), 71 (217), 99 (309), 122 (384), 129 (408), 195 (622)
Hepatocyte growth factor–Met interaction, 153 (477)
HER2, 9 (1)
HER3 down-regulation, 98 (307)
HER3 downregulation, 51 (144)
HER2 inhibitors, 115 (364)
HER2 staining, 194 (617)
HGF, 114 (361)
HIF-1 activation, 153 (478), 180 (571)
HIF-1a, 97 (303)
Hif1-a, 194 (619)
HIF signaling pathway, 27 (58), 40 (103), 57 (164)
High-throughput biomarker discovery, 200 (638)
Histone deacetylase inhibitors, 46 (124), 49 (135), 61 (178), 62 (184), 63 (185), 115 (364), 125 (394), 130 (411),

132 (416), 171 (537, 539), 172 (540, 542), 176 (554), 184 (584), 185 (589), 189 (601), 203 (652)

HIV-1 tat-conjugate, 186 (593)
Hormonal agents, 204 (654, 655), 205 (656, 657)
Host-specific response, 169 (531)
H295R cells, 57 (163)
hTERT, 198 (632)
Hydroxamate-tethered compounds, 171 (539)
Hypertension, 144 (455)
Hypoxia, heterogeneity imaging, 193 (616)

I

ICB2 transcription factor binding, 168 (526)
ICR62, 44 (118)
ID1, 171 (538)
Id-1, 92 (285)
Id4 expression, 185 (590)
IDO2 inhibitors, 206 (660)
IFN- γ , 161 (504)
IGF-1R inhibitors, 44 (116)
IGF-1R/IR inhibitors, 131 (412)
IGF receptor inhibitors, 99 (309)
IGF signaling pathway, 99 (309)
IGFR receptor inhibitors, 100 (314)
IL-4 levels in serum/tumours, 207 (663)
IL-17-producing cells, 205 (658)
Imaging biomarkers, 195 (623), 203 (650)
Imatinib, 121 (382)
Imetelstat sodium, 123 (388)
IMGN388, 152 (472)
Imidazoles, 61 (177), 62 (183)
Imidazotetraone prodrugs, 138 (438)
Immunoconjugates, 81 (246)
Immunofluorescence/AQUA, 196 (627)
Immunohistochemical assays, 3 (1LB)
Immunohistochemistry, 151 (469), 195 (621), 196 (627), 202 (649)
Immunohistochemistry/Western Blot analysis, 201 (643)
Immunomodulation, 207 (662)
Immunoproteomic biomarker screening, 200 (638)
Immunosuppression, 206 (659, 660)
Immunosurveillance, 207 (662)
Immunotherapy, 23 (46), 24 (47, 49), 25 (4LB, 5LB, 6LB), 111 (350), 149 (463), 161 (504)
Inecalcitol, 136 (430)
Inhibitor of apoptosis (IAP) proteins, 34 (82), 186 (592)
Inhibitor of apoptosis (IAP) proteins, antagonists, 125 (393)
INK128, 154 (482)
Insulin-(in)dependent mechanisms, 22 (40)
Insulinoma, 161 (504)
Interstitial fluid pressure (IFP), 135 (427)
Intestinal adenoma, 151 (471)
Invasive ductal carcinoma (IDC), 61 (179)
IPI-504, 69 (210)
Irinotecan, 64 (189)
Iron chelators, 103 (322)
Irvalec, 94 (292), 139 (439)
Isocitrate dehydrogenases, 56 (160)
Isoflurane anesthesia, 85 (261)
IT-101, 134 (423)
ITF2357, 171 (537)

J

J1 prodrug, 69 (208)
JFCR39 database, 36 (88)
JI-101, 66 (196), 127 (400)

JNJ-26481585, 49 (135), 189 (601)
 JNJ-26483327, 57 (165)
 Judemycin, 38 (97), 41 (107)
 JX-594, 128 (402)

K

Kaposi sarcoma, 127 (399)
 Ketoconazole (KET), 181 (574)
 Kinase activity profiling, 193 (615)
 Kinase inhibitors, 4 (4LB), 9 (2), 18 (27A), 20 (34), 22 (39), 25 (52), 26 (54), 27 (57), 28 (60, 62, 63), 29 (65), 31 (73), 32 (74, 75, 77), 33 (78, 79), 34 (83), 35 (87), 36 (88), 37 (93), 38 (96, 98), 39 (102, 99), 40 (105), 41 (108), 42 (109, 110), 43 (115), 44 (118, 119), 45 (122, 123), 46 (125), 48 (132, 133), 49 (134, 136, 137), 50 (138, 140), 51 (141, 142, 143), 53 (149, 151), 54 (153), 55 (157), 56 (162), 57 (165, 166), 58 (168), 59 (170, 171, 172, 173), 61 (177, 180), 62 (183), 63 (185, 188), 64 (190), 65 (194), 66 (197, 198), 67 (201), 68 (204, 205), 70 (213, 214), 71 (215, 216, 217), 72 (219), 82 (251), 83 (252, 253, 254, 2LB), 84 (257, 259), 99 (308), 100 (312), 102 (320), 107 (337), 108 (338), 109 (341, 343, 344), 110 (345), 113 (357), 116 (366, 368), 117 (370), 118 (373), 121 (383), 123 (387), 124 (391), 125 (395), 126 (396), 127 (399, 400, 401), 128 (403), 131 (412, 414), 133 (418, 419), 134 (421), 139 (441), 140 (443, 444, 445), 142 (451), 143 (453), 144 (455), 149 (465), 150 (466), 151 (471), 157 (493), 158 (494, 496), 159 (497, 498, 500), 160 (502, 503), 161 (505, 507), 163 (511, 512), 164 (514), 165 (518), 168 (527), 176 (556), 183 (583), 187 (595), 188 (600), 190 (605), 191 (608), 193 (615), 196 (627), 203 (651)
 Klf4, 200 (640)
 KP1339, 63 (188)
 KP46, 53 (150)
 KRAS amplification, 100 (312)
 KRAS mutations, 63 (187)
 KRas/Raf pathway, 56 (162)

L

L-MTP-PE, 206 (661)
 LA480, 74 (228)
 Lapatinib, radiolabelled, 4 (4LB)
 Laser capture microdissection (LCM), 202 (646)
 Laulimalide, 100 (313)
 LBH589, 124 (392)
 LC06, 156 (489)
 LC08, 156 (489)
 Leukemia, 95 (296), 185 (587), 186 (593)
 Linifanib, 188 (599)
 Liquid biopsy, 196 (626)
 Lithocholic acid, 94 (293)
 Liver cancer, 170 (532)
 Loss of heterozygosity (LOH), 61 (179)
 Lucanthone, 184 (586)
 Lung adenocarcinoma, 154 (479)
 Lung cancer, 59 (173), 68 (204), 73 (224), 91 (282), 95 (296), 162 (508), 172 (541), 174 (550), 182 (576), 200 (641)
 LY2523355, 3 (1LB)
 LY2603618, 67 (201), 165 (516)
 LY2606368, 65 (194)
 LY364947, 71 (217)
 Lyase inhibitors, 57 (163), 58 (167)
 Lymphoid malignancies, 192 (611)
 Lysosomal cell death, 22 (38)

M

MAGEA, 99 (311)
 Malignant gliomas, 185 (588)
 Malignant pleural mesothelioma (MPM), 173 (545)
 Mammaprint, 178 (563)
 Mammary adenocarcinoma, 171 (536)
 Mantle cell lymphoma (MCL), 44 (117), 65 (195), 182 (577)
 MAPK pathway, 40 (105), 83 (254), 103 (323), 118 (373)
 Maternal-fetal barrier, 176 (554)
 MCF-7 cancer cells, 204 (653)
 Mcl-1 inhibitors, 94 (290)
 MCP-1, 34 (82)
 MDV-3100, 71 (218)
 MEDI-573, 3 (3LB)
 MEDI-575, 39 (100), 128 (404)
 MEK 1/2, 116 (368)
 MEK/ERK pathway, 163 (511)
 MEK inhibitors, 188 (600)
 MEK pathway, 28 (60), 48 (132), 50 (138, 140), 53 (151), 56 (162), 68 (205)
 Mel-18/Bmi-1 complex, 171 (538)
 Melanoma, 40 (105), 78 (239), 83 (254), 84 (256), 126 (398), 130 (409), 131 (413), 153 (478), 165 (517)
 Melanoma cell migration inhibitor, 112 (355)
 Melphalan, 69 (208)
 Merkel cell carcinomas, 188 (597, 598)
 Merkel cell polyomavirus, 188 (597, 598)
 Mesenchymal stromal cells, 152 (473)
 Mesothelioma, 184 (584)
 MET addiction, 191 (607)
 MET amplification, 100 (312)
 MET antagonists, 76 (233)
 MET downregulation, 170 (532)
 MET expression, 98 (307)
 MET inhibitors, 52 (146), 53 (152), 68 (207), 117 (371), 126 (397, 398), 129 (406, 407, 408), 191 (607)
 Met inhibitors, 142 (451)
 Met kinase, 108 (338)
 MET pathway, 74 (228)
 Metabolomics, 40 (104)
 Metastatic lung cancer, 159 (499)
 Metastin analogues, 205 (656, 657)
 Metformin, 22 (40)
 Methylation, 166 (519)
 MGCD265, 125 (395), 126 (396)
 MGMT, 166 (519)
 MGN1703, 23 (46), 24 (47)
 Microarrays, 14 (15), 21 (37), 24 (48), 197 (630)
 MicroRNA-155, 58 (168)
 MicroRNA-205, 170 (535)
 MicroRNA-21, 198 (633)
 MicroRNA-221, 177 (561)
 MicroRNA-302-367 expression, 202 (647)
 MicroRNA analysis, 52 (145), 177 (558), 196 (625)
 MicroRNA-34b, 170 (533)
 MicroRNA engineering, 176 (557)
 Microtubule disruptors, 141 (446)
 Mismatch repair, 138 (438)
 Mithramycin, 37 (95)
 Mitochondrial apoptotic machinery, 183 (581)
 Mitochondrial membrane permeabilization, 183 (581)
 MK-1775, 203 (651)
 MK-4827, 114 (362)
 MLN4924, 130 (409)
 MLN9708, 199 (637)
 MM.1S multiple myeloma model, 50 (139)

MMP-9, 60 (175), 152 (475), 157 (490)
MNRP1685A, 118 (372)
Molecular analysis, 177 (559)
Molecular grading, 14 (14)
Molecular imaging, 9 (1), 78 (240), 149 (464)
Molecular imaging in vivo, 143 (452)
Molecular modeling, 30 (69)
Molecularly targeted agents (MTA), 115 (363), 142 (449)
Monocarboxylate transporter 1 (MCT1) inhibitors, 111 (351)
Monoclonal antibodies, 44 (116, 118), 69 (209), 74 (225, 227, 228), 75 (231), 76 (234), 78 (240, 241), 116 (367), 118 (372), 119 (377), 128 (404), 132 (415), 157 (490), 192 (613)
MPC-9528, 4 (5LB, 6LB)
MRLB-223, 46 (124)
MSC1936369, 118 (374)
MTAP expression, 173 (545)
mTOR, 25 (52), 27 (59), 35 (87), 42 (112), 43 (114), 53 (149), 54 (153), 55 (157), 64 (192), 65 (195), 70 (213), 83 (253), 121 (383), 123 (387, 389), 127 (399)
Multi-modality imaging, 85 (260)
Multicell layers, 135 (427)
Multicellular tumour spheroids (MTS), 93 (289)
Multidrug-resistant cancer cells, 76 (235), 97 (300)
Multimodal therapy, 155 (484)
Multiparametric magnetic resonance imaging, 87 (266)
Multiple myeloma, 34 (84), 50 (139), 93 (288), 109 (341), 120 (379), 183 (580)
Multitargeted therapy, 115 (364)
Myeloma, 100 (314)
Myelotoxicity assessment, 144 (457)
Myxoid liposarcomas (MLS), 90 (278), 102 (318)

N

N-glycosylation, 105 (330)
Nampt inhibitors, 4 (5LB, 6LB)
Nanopharmaceuticals, 17 (24), 82 (249), 134 (423), 135 (425), 136 (429), 176 (555)
Navitoclax, 192 (611)
NBRI16716A, 138 (436)
NC-001, 90 (279)
NCI, 94 (291)
NCI-H292 cell line, 62 (181)
Necitumumab, 35 (85), 52 (145)
Nedd8 activation inhibitors, 130 (409)
NEK2 kinase, 109 (341)
NeoBIG, 16 (18)
Neratinib, 143 (454)
Neuroendocrine cancer cells, 156 (487)
Neuroendocrine tumours of the pancreas, 154 (481)
Neuropilin 2 expression, 207 (662)
Newcastle disease virus (NDV), 171 (536)
NF- κ B, 97 (303)
Nitrosative stress, 46 (126)
NMS-1116354, 49 (136), 122 (385)
NMS-E628, 59 (170)
NMS-P118, 166 (520)
NMS-P506, 52 (147)
NMS-P626, 39 (102)
NOCI, 15 (16)
Non-Hodgkin lymphoma (NHL), 81 (247), 189 (602)
non-Hodgkin lymphoma (NHL), 93 (288), 120 (379)
Notch-1 fragment peptide, 186 (593)
Notch signaling pathway, 30 (69), 36 (89)
NOXA, 184 (585)

NPD3483, 95 (294)
NPD723, 95 (296)
NPM-ALK mediated signaling, 112 (352)
NSCLC, 29 (64), 30 (68), 31 (73), 35 (85), 39 (100), 50 (138), 51 (142), 52 (145), 54 (155), 59 (170), 62 (181), 68 (206, 207), 69 (210), 98 (304), 99 (308, 311), 106 (333), 109 (343), 117 (369), 126 (397), 130 (410), 134 (421), 137 (433), 150 (467), 170 (533), 173 (546), 179 (566), 183 (582), 191 (609), 193 (614), 198 (633), 200 (641)
NSCLC molecular subtypes, 84 (259)
NVP-BEZ235, 43 (114), 66 (198)

O

Obatoclax, 57 (166)
Octamers, 178 (562)
Ocular toxicity, 119 (375)
Oesophageal adenocarcinoma, 190 (606)
Oesophagogastric cancer, 199 (635)
Off-target effect, 182 (578)
Olaparib, 4 (6LB), 128 (405), 132 (417)
Oleanolic acid derivatives, 103 (321)
Oligonucleotides, 178 (562)
Ombrabulin, 122 (386)
OMP-21M18, 73 (222)
OncoMap, 21 (35)
Onconase, 137 (433)
Oncotest panel, 48 (131)
Organic anion-transporting polypeptides (OATP), 112 (354), 201 (642)
Orthotopic colorectal cancer model, 86 (264)
Orthotopic mouse models, 87 (269), 88 (271), 89 (273), 91 (282), 169 (530)
Orthotopic transplant model, 64 (190)
Orthotopic xenograft models, 48 (133), 91 (280), 169 (530)
OSNA test, 178 (564)
Osteolysis inhibition, 50 (139)
Osteosarcoma, 65 (193)
Ovarian cancer, 21 (35), 64 (189), 69 (208), 103 (323), 105 (328), 107 (336), 110 (347), 114 (362), 128 (405), 129 (407), 164 (515), 165 (518), 174 (548), 179 (569)
Oxaliplatin derivatives, 141 (447)
Oxi4503, 120 (380)
Oxidative stress, 25 (51)
Oxidative stress modulators, 70 (212)
Ozonotherapy, 111 (350)

P

P529, 26 (55)
p53, 81 (245), 97 (303), 139 (442)
p53 activation, 22 (41), 29 (66)
P-cadherin, 119 (377)
p53 deficiency, 81 (243)
P-glycoprotein, 105 (330), 160 (501)
P-glycoprotein expression, 103 (322)
P-glycoprotein inhibitors, 105 (328)
p53/MDM2/ERK pathway, 185 (588)
p53-NLS-11R peptide, 185 (588)
p53 pathway, 203 (652)
Paclitaxel, 39 (100), 78 (239), 131 (412), 134 (421), 150 (467)
Paediatric cancer, 49 (135), 70 (214), 114 (360, 361), 164 (514), 166 (519), 177 (561), 184 (585), 199 (636)
PAK1, 109 (343)
Pancreatic cancer, 44 (118), 53 (151), 69 (209), 86 (265), 94 (290, 292), 97 (302), 111 (348), 154 (481), 169 (530), 176 (556), 191 (610), 193 (615)

- Pancreatic ductal adenocarcinoma (PDAC)**, 86 (265), 87 (266), 88 (271)
- Panitumumab**, 113 (358)
- Panobinostat**, 130 (411)
- Paracrine signalling**, 155 (485)
- PARP inhibitors**, 4 (6LB), 64 (189), 81 (244), 114 (362), 132 (417), 164 (515), 166 (520)
- Patient-derived tumour cells**, 145 (459)
- Patient-derived tumour models**, 92 (284)
- Patient-derived xenografts**, 89 (275), 96 (299), 198 (634)
- Patient selection**, 83 (254), 189 (603), 191 (607), 193 (614)
- Patient-tumour derived xenograft models**, 85 (262)
- Pazopanib**, 25 (50)
- PCR assays**, 93 (287)
- PDGFR- α** , 128 (404)
- PDGFR inhibitors**, 66 (196), 127 (400)
- PDL192**, 29 (64), 37 (94)
- Pediatric Preclinical Testing Program**, 49 (135)
- Peloruside A**, 100 (313)
- Pemetrexed**, 67 (201), 124 (390), 165 (516, 517), 173 (545)
- Penile cancer**, 194 (617), 202 (649)
- Perifosine**, 67 (203)
- Perisporiopsis melioides***, 138 (436)
- PET imaging**, 4 (4LB), 120 (380), 186 (594), 193 (616), 203 (650)
- PF-01367338**, 164 (515)
- PF-03732010**, 119 (377)
- PF-04691502**, 121 (383)
- PF-05212384**, 123 (387)
- PF-113**, 119 (375)
- PHA-767491**, 161 (505)
- Pharmacodynamic assay development**, 187 (596)
- Pharmacodynamic markers**, 13 (8)
- Pharmacodynamics**, 17 (24, 25), 34 (82), 66 (196), 77 (237), 86 (263), 93 (288), 115 (364, 365), 116 (368), 118 (373, 374), 119 (377), 123 (388, 389), 125 (393), 131 (413, 414), 181 (573), 188 (600), 199 (637), 203 (651), 206 (661)
- Pharmacoeugenetics**, 13 (9)
- Pharmacogenetic screening**, 175 (552)
- Pharmacogenetics**, 13 (11), 14 (12)
- Pharmacokinetic/pharmacodynamic modelling**, 133 (420)
- Pharmacokinetics**, 17 (24, 25), 25 (50), 34 (82), 62 (183), 66 (196), 77 (237), 93 (288), 104 (325), 109 (344), 115 (364, 365), 116 (368), 118 (373, 374), 119 (377), 121 (382, 383), 122 (385), 123 (387, 388, 389), 125 (393), 127 (401), 131 (414), 132 (415), 133 (419), 143 (453), 144 (458), 175 (553), 181 (573, 574), 182 (576), 188 (600), 199 (637), 206 (661)
- Phase I/II studies**, 122 (384)
- Phase I studies**, 3 (3LB), 23 (46), 24 (47), 25 (50), 28 (62), 29 (64), 71 (216), 73 (222), 74 (227), 76 (234), 93 (288), 101 (316), 104 (325, 326), 115 (363, 364, 365), 116 (366, 367, 368), 117 (370), 118 (372, 374), 119 (375, 376, 377), 120 (379, 380), 122 (385, 386), 123 (389), 124 (391, 392), 125 (393, 394), 127 (400), 128 (403, 404), 130 (409, 411), 131 (412, 414), 132 (415, 416), 133 (418, 419), 134 (421, 423), 135 (426), 137 (432, 434), 142 (449), 143 (453), 149 (465), 152 (472), 157 (491), 158 (494, 496), 163 (512), 165 (516), 172 (542), 180 (570), 181 (574, 575), 187 (596), 189 (603), 192 (611), 205 (656)
- Phase II studies**, 24 (48), 88 (271), 91 (281), 117 (371), 120 (378), 126 (397, 398), 129 (406, 407, 408), 130 (410), 131 (413), 139 (439), 150 (467), 172 (540), 193 (614)
- Phase III trials**, 149 (460)
- Phosphopeptide mimetic prodrugs**, 134 (422)
- Phosphorylated histone proteins**, 201 (643)
- PI3K/mTOR pathway**, 18 (27A)
- PI3K pathway**, 23 (43), 25 (52), 28 (60), 29 (65), 30 (67), 32 (74), 35 (87), 36 (88), 37 (93), 38 (98), 40 (104), 41 (108), 43 (114, 115), 45 (122), 47 (128), 48 (132, 133), 49 (134), 50 (138, 140), 51 (141, 142), 53 (149), 61 (177), 62 (183), 66 (197, 198), 72 (219), 83 (253), 110 (345, 347), 116 (366), 121 (383), 123 (387, 389), 131 (414), 134 (421), 138 (435), 140 (444), 150 (466), 183 (583), 187 (595), 190 (605), 196 (627)
- PIM kinases**, 45 (123), 124 (391)
- Pirin inhibition**, 112 (355)
- Placental growth factor**, 154 (481)
- Platinum cytotoxicity**, 99 (311)
- Platinum drugs**, 206 (659)
- Platinum resistance**, 166 (522), 199 (635)
- Platinum salts**, 122 (386)
- Plitidepsin**, 137 (432)
- Plucked hair as surrogate biomarker**, 202 (648)
- PLX4720**, 31 (71)
- PM01183**, 137 (434), 166 (522)
- Polo-like kinase 1**, 159 (498), 160 (503), 177 (560)
- POLQ expression**, 106 (332)
- Polycomb group proteins**, 171 (538)
- Polymerase inhibitors**, 128 (405)
- Polymorphisms**, 14 (12)
- Poxvirus**, 128 (402)
- Preclinical cancer models**, 92 (283)
- Preclinical studies**, 23 (45), 28 (60), 34 (81, 83), 38 (96, 97, 98), 39 (102), 40 (105), 41 (106), 57 (165), 61 (180), 66 (196), 88 (270)
- Prednisone**, 136 (430)
- Primary cell cultures**, 95 (295), 96 (299)
- Prodrugs**, 124 (390)
- Prognostic marker**, 14 (15)
- Prognostic markers**, 18 (26), 19 (28), 21 (37), 152 (474), 170 (534), 191 (610), 194 (617, 619), 198 (632), 205 (658)
- Prognostic tests**, 178 (563)
- Programmed cell death 4 (PDCD4) protein**, 198 (633)
- Prostate adenocarcinoma**, 207 (663)
- Prostate cancer**, 18 (27A), 28 (61), 40 (103), 42 (111), 62 (184), 137 (431), 138 (436), 151 (470), 152 (475), 158 (495), 161 (506), 167 (523, 524), 177 (558), 185 (590), 196 (625), 200 (640), 201 (642), 205 (657)
- Prostate carcinoma allografts**, 151 (469)
- Protease inhibitors**, 152 (475)
- Proteasome inhibitors**, 53 (150), 64 (192), 120 (379), 199 (637)
- Protein kinase CK2**, 165 (518)
- Protein kinase N3 (PKN3)**, 176 (556)
- Protein-protein interactions**, 139 (442)
- Proteomic classifier**, 193 (614)
- PTEN**, 30 (67), 40 (104), 61 (179)
- PTEN silencing**, 127 (399)
- PX-866**, 116 (366)
- Pyrazolo[4,3-*d*]pyrimidine derivatives**, 159 (500)
- Pyrazolopyrimidine derivatives**, 54 (153)
- Pyrrollobenzodiazepine (PBD) conjugates**, 168 (526, 528)
- Pyrrollobenzodiazepine (PBD) prodrugs**, 167 (525)
- Q**
- Q141K polymorphism**, 176 (554)
- Quantitative RT-PCR**, 89 (273)
- Quercetin**, 97 (302)

R

R1507, 44 (116)
Rac1, 86 (265)
Radiation-induced toxicity, 167 (523)
Radionuclide therapy, 82 (250)
Radioresistance, 170 (533)
Radioresistance biomarkers, 201 (644)
Radiosensitization, 31 (71), 35 (87)
Radiotherapy, 10 (4), 17 (23), 87 (269)
RAF, 46 (125)
RAF/MEK inhibitor, 115 (365)
Rapamycin, 127 (399)
Ras-MAPK pathway, 29 (65)
Receptor oligomerization, 107 (337)
Rectal cancer, 63 (187)
REGN421/SAR153192, 74 (227)
Renal cancer, 70 (213), 90 (279)
Renal cell carcinoma, 154 (482), 155 (483), 191 (608), 194 (618, 619), 195 (623)
Renal cell carcinoma (RCC), 72 (221)
Reolysin, 183 (580)
Resminostat, 172 (540, 542)
Resveratrol analogues, 96 (297)
RET inhibitors, 117 (371), 126 (397, 398), 129 (406, 407, 408)
Reverse phase protein arrays, 106 (333), 196 (627)
RGB-286638, 128 (403)
RGC32 downregulation, 173 (546)
Rhabdomyosarcoma, 114 (360, 361), 163 (511)
RHM Prognostic score, 189 (603)
RING1b, 171 (538)
RNA amplification, 24 (48)
RNA antagonists, 51 (144)
RNA-seq, 84 (255, 3LB)
RNAi therapeutic, 176 (555)
rNCP12.1, 169 (531)
RO5126766, 115 (365)
RON expression, 3 (2LB)
RON tyrosine kinase, 110 (346)
Rosuvastatin, 121 (382)
RUNX3, 156 (488)
Runx2 stimulation, 190 (604)

S

S-nitrosothiol homeostasis, 46 (126)
Salmonella enterica, 66 (199)
Sarcomas, 14 (14), 203 (650)
SB939, 132 (416)
4SC-202, 61 (178)
4SC-207, 160 (501)
SCH900776, 158 (494)
Schwannoma, 42 (110)
SCLC, 44 (116), 59 (171), 158 (495)
Sensitivity enhancement, 26 (55)
Sensitization, 32 (77), 43 (114), 44 (116), 52 (148), 59 (172), 69 (211), 97 (301), 106 (332), 161 (506, 507), 162 (508, 509), 163 (510, 511), 164 (513, 514), 168 (527), 186 (591)
SEPT9v1, 57 (164)
SET protein, 172 (543)
SGI-110, 173 (547)
Shh signaling, 156 (488)
Side effects, 18 (26), 92 (286)
Simulation studies, 144 (455)
Single nucleotide polymorphisms (SNPs), 197 (629)
siRNA, 81 (247)
SIRT2, 25 (51)

SJG-136, 91 (281)
Skin toxicity, 144 (456)
Slit2, 156 (487)
Small interfering RNAs, 177 (560)
Small-molecule antagonists, 186 (592)
Small-molecule EGFR inhibitors, 113 (358)
Small-molecule IDH enzyme inhibitors, 56 (160)
Small-molecule IL-6 inhibitors, 43 (113)
Small-molecule inhibitors, 82 (251), 83 (2LB), 109 (341), 114 (360), 121 (383), 123 (387), 151 (471), 160 (503), 163 (512), 184 (586), 187 (596)
Small-molecule inhibitors of ATM, 81 (245)
Small-molecule kinase inhibitors, 28 (63), 37 (93), 39 (99), 41 (106), 48 (133), 59 (170)
Small-molecule splicing modulators, 38 (97), 41 (107)
SMO antagonists, 60 (174)
Solid tumours, 3 (3LB), 23 (46), 24 (47), 25 (50), 33 (78), 40 (105), 73 (222), 74 (226), 76 (234), 93 (288), 115 (365), 116 (367, 368), 117 (371), 118 (372, 374), 119 (377), 120 (379), 122 (385, 386), 123 (388), 124 (391, 392), 125 (394), 128 (403, 404, 405), 130 (411), 131 (412), 132 (415), 133 (418, 419, 420), 134 (423), 135 (426, 427), 137 (432), 149 (465), 152 (472), 162 (509), 164 (514), 176 (555), 180 (570, 571), 181 (574, 575), 188 (599)
Soluble Axl, 200 (639)
Somatostatin analogues, 82 (250)
Sorafenib, 57 (166), 58 (168), 61 (180), 63 (188), 64 (190), 92 (283), 97 (302), 131 (413), 151 (469), 193 (614)
Spermidine-CoA derivatives, 164 (513)
Splicing factors, 107 (336)
Sprycel, 59 (172), 63 (186)
Src family kinases (SFKs), 63 (185)
STAT6 knockdown, 206 (659)
Stat3 pathway, 40 (103), 43 (113), 81 (247), 134 (422)
Statins, 34 (84), 58 (169)
Stem cell markers, 197 (628)
Stem cells, 9 (3), 10 (4, 5, 6), 82 (248)
Stemness signature, 200 (640)
Stereoisomerism, 141 (447)
Structure analysis, 4 (4LB, 5LB), 139 (441, 442), 140 (443, 444, 445), 141 (446, 447, 448), 154 (480), 159 (500), 167 (525), 168 (526)
Structure-activity relationship, 38 (97)
Strychnine, 204 (653)
SU11274, 52 (146)
Sulforaphane, 97 (302)
Sunitinib, 104 (324)
Survivin expression, 185 (587)
Syk kinase, 100 (314)
Synthetic lethality, 81 (242)
Systemic therapies, 84 (256)

T

T-DM1, 35 (86)
Tab2, 101 (315)
TAK-448, 205 (656)
TAK-463, 205 (656)
TAK-683, 205 (657)
TAK-700, 57 (163), 58 (167)
TAK-733, 188 (600)
TAK-960, 159 (498), 160 (503)
Tamoxifen, 101 (315), 175 (553), 204 (654)
Targeted therapy, 9 (2), 13 (8), 16 (22), 17 (23, 25), 18 (26), 20 (32, 33, 34, 1LB), 22 (38, 39, 40), 23 (42, 43), 26 (53, 56), 27 (59), 28 (61), 29 (65), 30 (67, 69), 32 (76),

Targeted therapy (cont'd)

33 (80), 35 (87), 36 (91), 37 (95), 41 (107), 42 (109, 110, 112), 44 (117), 45 (121), 46 (124, 125), 48 (131), 51 (144), 52 (148), 54 (155), 55 (157, 159), 64 (192), 74 (226), 75 (231), 77 (236), 81 (243, 244, 245, 247), 82 (248, 249, 250, 251), 83 (254, 2LB), 84 (255, 259, 3LB), 86 (265), 89 (273), 94 (290), 98 (306), 101 (315), 103 (323), 106 (331, 332), 107 (334, 336), 108 (339), 109 (342), 110 (347), 111 (348, 349, 350, 351), 112 (352, 354, 355), 113 (357), 120 (378), 127 (400), 128 (402, 404), 134 (422), 136 (428), 149 (463), 152 (472), 154 (481), 157 (490), 164 (513), 168 (526, 527), 171 (537), 173 (544), 176 (556), 177 (561), 184 (585), 189 (602), 191 (607), 193 (615), 201 (643), 203 (652)

Targeted therapy, 161 (505)

Targeting peptides, 136 (428)

Tasisulam-sodium, 92 (286)

Taxane resistance, 199 (635)

Taxanes, 122 (386)

TCF7L2 silencing, 97 (301)

Telomerase inhibitors, 123 (388)

Temozolomide, 36 (89), 52 (148), 60 (176), 98 (305), 165 (517)

Temzolomide, 138 (438)

Terminal end buds, 92 (285)

Testosterone release suppression, 205 (656)

Tetrahydroisoquinoline-based systems, 141 (446)

Tetravalent bispecific antibody (TAVi6), 150 (468)

TG02, 33 (78), 34 (83)

TGF- β , 55 (159), 71 (217), 113 (359), 169 (530)

TGF- β polymorphisms, 197 (629)

TH-302, 124 (390)

Therapeutic antibodies, 77 (238)

Therapy modelling, 178 (565), 179 (568)

Therapy resistance, 101 (317), 108 (340), 160 (501), 184 (584), 191 (608, 609), 199 (635), 204 (655)

Three-dimensional cultures, 93 (289)

Three-dimensional specimen imaging, 195 (621)

Three-dimensional tumour models, 55 (158)

Thymidine kinase, 168 (527)

Thymidylate synthase (TS) inhibition, 67 (201), 102 (320), 165 (517), 168 (527)

Thymoma, 84 (258)

Thyroid cancer, 31 (71), 84 (257)

Tie inhibitors, 51 (141)

Tigatuzumab, 29 (66), 78 (240), 132 (415)

Tivozanib, 36 (90), 117 (370)

Tivozanib response marker, 191 (608)

TLC388, 180 (571)

T790M mutation, 68 (206, 207)

TNF, 161 (504)

TNF- α polymorphisms, 182 (579)

Toll-like receptors, 23 (46), 24 (47)

Topoisomerase inhibitors, 180 (571, 572)

TORC1/2 inhibitors, 154 (482)

Trabectedin, 90 (278), 102 (318)

Trabedersen, 113 (359), 169 (530)

TRAIL, 82 (248), 186 (591)

Transcription factor regulation, 172 (543)

Transcriptome sequencing, 84 (255, 3LB)

Transferrin receptor binding peptide, 109 (342)

Transposable elements, 174 (549)

Trastuzumab-DM1, 73 (223), 77 (237)

TRC102, 165 (517)

TRC105, 116 (367)

Trial design, 15 (16, 17), 16 (18, 22), 17 (25), 19 (28, 29), 20 (32), 58 (169)

Triarylpyrroles, 139 (442)

Tributylin, 203 (652)

Trojan Horse liposomes (THL), 136 (429)

Tropomyosin, 107 (334)

Tubulin inhibitors, 100 (313), 120 (380), 122 (386), 150 (467), 181 (573, 575)

Tumor grading, 14 (14)

Tumor imaging, 33 (80)

Tumor-induced endothelial cells (TEC), 23 (44)

Tumour cell integrity, 139 (439)

Tumour characterization, 156 (486), 175 (551), 177 (559), 179 (569), 184 (584), 196 (624, 626), 197 (628), 198 (634)

Tumour-colonizing bacteria, 66 (199)

Tumour detection in vivo, 186 (594)

Tumour hypoxia, 102 (319), 161 (507)

Tumour-initiating cells (TICs), 70 (214), 73 (224), 151 (470)

Tumour mechanisms, 92 (285), 97 (303), 110 (346), 171 (538), 172 (541), 173 (546), 174 (548, 549), 177 (558)

Tumour microenvironment, 149 (462), 155 (485), 157 (490)

Tumour models, 3D, 55 (158)

Tumour penetration, 77 (238)

Tumour perfusion, 120 (380)

Tumour progression, 154 (479)

Tumour stem cells, 87 (268)

Tumour vascular structure suppression, 150 (466)

Tumour-stroma cell interaction, 138 (436)

TweakR, 29 (64), 37 (94)

TYRP1 mRNA, 14 (15)

U

U0126, 163 (511)

U3 1287, 76 (234)

Ubiquitin-proteasome system, 36 (91), 47 (127)

Uridine phosphorylase, 141 (448)

Uveal melanoma, 90 (277)

V

Vaccination, 23 (44)

Vandetanib, 130 (410)

Vascular disrupting agents (VDA), 86 (263), 122 (386), 128 (402), 150 (467)

VDR agonists, 136 (430)

VEGF, 30 (70), 117 (370)

VEGF imaging, 72 (221)

VEGF-PET, 9 (1)

VEGFR inhibitors, 51 (141), 64 (191), 66 (196), 117 (371), 126 (397, 398), 127 (400), 129 (406, 407, 408)

VeriStrat, 193 (614)

Vesicular stomatitis virus (VSV), 169 (531), 176 (557)

Vinblastine, 138 (437)

Virtual Tumour, 178 (565)

Vorinostat, 44 (117), 46 (124), 184 (584)

W

Wee1 tyrosine kinase, 203 (651)

Whole-genome sequencing, 179 (569)

Wnt signaling, 31 (72)

Wogonin, 138 (435)

X

Xenografts, 32 (75), 35 (85), 37 (94), 39 (100, 99), 40 (104), 45 (120, 123), 48 (131), 51 (142), 54 (154), 59 (170, 171), 60 (174), 62 (182), 68 (207), 70 (214), 72 (220), 77 (237, 238), 85 (261, 262), 89 (274, 275, 276), 90 (278, 279), 91 (280), 98 (304), 106 (333), 138 (436),

Xenografts (*cont'd*)

156 (489), 157 (493), 166 (520), 167 (524), 188 (599),
193 (615), 196 (624), 197 (628)

Xenografts, characterization, 89 (275, 276)

XL184, 117 (371), 126 (397, 398), 129 (406, 407, 408)

XMT-1001, 180 (570)

XRCC1 Arg280His polymorphism, 167 (523)

Z

Zalypsis, 88 (271)

Zibotentan, 42 (111), 56 (161)

⁸⁹Zr-bevacizumab PET imaging, 72 (221)